Stanley Capital Partners LLP (SCP) announced the acquisition of MyMeds&Me Limited (MMM) by its portfolio company Drug Safety and Pharmacovigilance Services Solutions (DSS). DSS is a global provider of pharmacovigilance services under the brand Bioclinica. The financial terms of the transaction are not being disclosed.
The combined, digital-first organization will provide a pharmacovigilance solution focused on the current and future requirements of the life sciences industry.
Read more about the acquisiton here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.